secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2025-01-02T23:59:59+00:00
Accession:  0001818331-25-000002
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeneDx appoints Bryan Dechairo as COO with $450K salary and $2.7M RSU award
---------------------------------------------------------------------------

- Bryan Dechairo appointed COO effective Jan 2, 2025; reports to CEO Katherine Stueland.
- Total annual base salary of $450,000 plus target annual bonus of 50% of base salary.
- RSUs with $2.7M grant-date value vesting over 4 years; sign-on bonuses of $75K each in 2025 and 2026.
- Dechairo previously CEO of Sherlock Biosciences; will oversee Product & Technology, Operations, Medical Affairs, Innovation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833125000002/0001818331-25-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833125000002/wgs-20250102.htm
  HTML page:      https://secwatch.observer/filing/0001818331-25-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer